PF-06952229

PF-06952229

P655695-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer In Vivo PF-06952229 (oral gavage; 30 mg/kg; twice daily; 21 days) combines with Palbociclib 21 days results in an improved inhibition of pSMAD2 in the MCF7 ER + xenograft breast cancer tumor model. This combination also leads to a significant increase in survival relative to PF-06952229 monotherapy . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MCF-7 ER + HER2-xenograft breast cancer tumor model Dosage: 30 mg/kg Administration: Oral gavage; twice daily; 44 days Result: Resulted in an increase in tumor growth inhibition when combined with Palbociclib. IC50& Target:IC50: transforming growth factor-beta receptor 1 (TGFbR1)

PF-06952229 是一种强效、选择性和口服活性 TGFbR1 抑制剂。PF-06952229 能特异性地与 TGFbR1 结合，阻止 TGFbR1 介导的信号转导。

1801333-55-0(DMSO)

C23H24ClFN4O3

458.91 g/mol

CC(C)C1=CN=C(C=C1NC2=C(C=NC=C2)C(=O)NC(CO)CO)C3=C(C=CC(=C3)Cl)F